A new study published in The American Journal of Pathology found that inhibiting the sterol regulatory element-binding protein (SREBP) can help overcome docetaxel resistance in advanced prostate cancer.
Docetaxel is a common chemotherapy treatment for prostate cancer, but patients eventually develop resistance to it. The study found that combining docetaxel with mifepristone significantly reduced cancer cell viability. Researchers identified that SREBP-1, a transcription factor involved in cholesterol and lipid biosynthesis, plays a central role in docetaxel resistance. Inhibiting SREBP-1 and the processes it regulates could be a promising approach to improve the effectiveness of docetaxel-based chemotherapy for advanced prostate cancer.
Supraphysiological Androgens [SPA] Promote Tumor Suppressive Activity of the AR Through cMYC Repression and Recruitment of the DREAM Complex
Seminal Vesicle Invasion & Senescent tumor cells.